134 related articles for article (PubMed ID: 25081047)
1. Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study.
O'Carrigan B; Fournier M; Olver IN; Stockler MR; Whitford H; Toner GC; Thomson DB; Davis ID; Hanning F; Singhal N; Underhill C; Clingan P; McDonald A; Boland A; Grimison P;
Intern Med J; 2014 Aug; 44(8):813-7. PubMed ID: 25081047
[TBL] [Abstract][Full Text] [Related]
2. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy.
Khanal N; Ahmed SS; Kalra M; Miller TJ; Brames MJ; Stump TE; Monahan P; Hanna NH; Einhorn LH
Support Care Cancer; 2020 Jul; 28(7):3165-3170. PubMed ID: 31707501
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors.
Kurobe M; Kawai K; Suetomi T; Iwamoto T; Waku N; Kawahara T; Kojima T; Joraku A; Miyazaki J; Nishiyama H
Int J Urol; 2018 May; 25(5):457-462. PubMed ID: 29478250
[TBL] [Abstract][Full Text] [Related]
4. Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment.
Pühse G; Secker A; Kemper S; Hertle L; Kliesch S
Int J Androl; 2011 Oct; 34(5 Pt 2):e351-7. PubMed ID: 21062302
[TBL] [Abstract][Full Text] [Related]
5. Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy.
Lackner JE; Koller A; Schatzl G; Marberger M; Kratzik C
Urology; 2009 Oct; 74(4):825-9. PubMed ID: 19589582
[TBL] [Abstract][Full Text] [Related]
6. Hypogonadism and androgen deficiency symptoms in testicular cancer survivors.
Lackner JE; Märk I; Schatzl G; Marberger M; Kratzik C
Urology; 2007 Apr; 69(4):754-8. PubMed ID: 17445664
[TBL] [Abstract][Full Text] [Related]
7. Effect of Testosterone Replacement Therapy on Quality of Life and Sexual Function in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency: Results From a Randomized Double-blind Trial.
Højer EG; Kreiberg M; Dehlendorff C; Jørgensen N; Juul A; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
Clin Genitourin Cancer; 2022 Aug; 20(4):334-343. PubMed ID: 35514022
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Willemse PM; Burggraaf J; Hamdy NA; Weijl NI; Vossen CY; van Wulften L; van Steijn-van Tol AQ; Rosendaal FR; Osanto S
Br J Cancer; 2013 Jul; 109(1):60-7. PubMed ID: 23660945
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of vertebral fractures independent of BMD and anticancer treatment in patients with testicular germ cell tumors.
Willemse PM; Hamdy NA; van Wulften L; van Steijn-van Tol AQ; Putter H; Osanto S
J Clin Endocrinol Metab; 2010 Nov; 95(11):4933-42. PubMed ID: 20702527
[TBL] [Abstract][Full Text] [Related]
11. Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals.
Brabrand S; Fosså SD; Cvancarova M; Lehne G
BJU Int; 2011 Apr; 107(7):1080-7. PubMed ID: 20825398
[TBL] [Abstract][Full Text] [Related]
12. Re: Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Seftel A
J Urol; 2013 Nov; 190(5):1768. PubMed ID: 24120785
[No Abstract] [Full Text] [Related]
13. Vitamin D status among long-term survivors of testicular cancer.
Schepisi G; De Padova S; Scarpi E; Lolli C; Gurioli G; Menna C; Burgio SL; Rossi L; Gallà V; Casadio V; Salvi S; Conteduca V; De Giorgi U
Oncotarget; 2017 May; 8(22):36780-36786. PubMed ID: 28030821
[TBL] [Abstract][Full Text] [Related]
14. What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention.
Poniatowska G; Michalski W; Kucharz J; Jonska-Gmyrek J; Wieszczy P; Nietupski K; Demkow T; Dedecjus M; Sadowska M; Kalinowski T; Grochulska-Nalazek B; Nowatorska A; Stelmasiak P; Wiechno PJ
Med Oncol; 2020 Aug; 37(9):82. PubMed ID: 32767179
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of quality of life, anxiety and depression in testicular cancer patients during chemotherapy and after anticancer treatment].
Osmańska M; Borkowska A; Makarewicz R
Psychiatr Pol; 2010; 44(4):543-56. PubMed ID: 20919505
[TBL] [Abstract][Full Text] [Related]
16. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110
[TBL] [Abstract][Full Text] [Related]
17. Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer.
Ondrusova M; Ondrus D; Dusek L; Spanikova B
Neoplasma; 2009; 56(6):473-9. PubMed ID: 19728753
[TBL] [Abstract][Full Text] [Related]
18. Long-term Morbidity of Testicular Cancer Treatment.
Fung C; Fossa SD; Williams A; Travis LB
Urol Clin North Am; 2015 Aug; 42(3):393-408. PubMed ID: 26216826
[TBL] [Abstract][Full Text] [Related]
19. Comment on 'Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'.
Singhera M; Huddart R
Br J Cancer; 2013 Oct; 109(9):2502-3. PubMed ID: 24045657
[No Abstract] [Full Text] [Related]
20. Reply: 'Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'.
Willemse PM; Burggraaf J; Hamdy NA; Osanto S
Br J Cancer; 2013 Oct; 109(9):2503-4. PubMed ID: 24045664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
